Raymond James & Associates’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $1.48M | Buy |
74,602
+26,231
| +54% | +$521K | ﹤0.01% | 2420 |
|
|
2024
Q2 | $749K | Sell |
48,371
-8,622
| -15% | -$134K | ﹤0.01% | 2810 |
|
|
2024
Q1 | $908K | Buy |
56,993
+6,714
| +13% | +$107K | ﹤0.01% | 2647 |
|
|
2023
Q4 | $845K | Buy |
50,279
+2,045
| +4% | +$34.4K | ﹤0.01% | 2609 |
|
|
2023
Q3 | $564K | Buy |
48,234
+457
| +1% | +$5.34K | ﹤0.01% | 2801 |
|
|
2023
Q2 | $642K | Sell |
47,777
-7,907
| -14% | -$106K | ﹤0.01% | 2747 |
|
|
2023
Q1 | $923K | Buy |
55,684
+13,371
| +32% | +$222K | ﹤0.01% | 2484 |
|
|
2022
Q4 | $787K | Buy |
42,313
+13,113
| +45% | +$244K | ﹤0.01% | 2564 |
|
|
2022
Q3 | $375K | Buy |
29,200
+6,876
| +31% | +$88.3K | ﹤0.01% | 3025 |
|
|
2022
Q2 | $156K | Buy |
+22,324
| New | +$156K | ﹤0.01% | 3556 |
|
|
2021
Q1 | – | Sell |
-11,726
| Closed | -$39K | – | 3842 |
|
|
2020
Q4 | $39K | Hold |
11,726
| – | – | ﹤0.01% | 3572 |
|
|
2020
Q3 | $35K | Sell |
11,726
-6,000
| -34% | -$17.9K | ﹤0.01% | 3406 |
|
|
2020
Q2 | $82K | Sell |
17,726
-1,000
| -5% | -$4.63K | ﹤0.01% | 3281 |
|
|
2020
Q1 | $72K | Sell |
18,726
-8,407
| -31% | -$32.3K | ﹤0.01% | 3242 |
|
|
2019
Q4 | $102K | Buy |
27,133
+4,126
| +18% | +$15.5K | ﹤0.01% | 3430 |
|
|
2019
Q3 | $122K | Buy |
23,007
+5,500
| +31% | +$29.2K | ﹤0.01% | 3333 |
|
|
2019
Q2 | $67K | Buy |
17,507
+4,500
| +35% | +$17.2K | ﹤0.01% | 3417 |
|
|
2019
Q1 | $66K | Sell |
13,007
-2,000
| -13% | -$10.1K | ﹤0.01% | 3406 |
|
|
2018
Q4 | $29K | Buy |
15,007
+2,500
| +20% | +$4.83K | ﹤0.01% | 3378 |
|
|
2018
Q3 | $47K | Buy |
+12,507
| New | +$47K | ﹤0.01% | 3443 |
|